We use cookies to make it easier for you to use our website and give you a better experience. We aggregate the information we get through cookies from users like you, and analyze that data to better understand user behavior and help us improve the website. We do not give or sell the data you provide through cookies to any third party for any purpose (such as advertising or marketing). By using this website, you consent to Organogenesis using cookies for these purposes. You may change your settings anytime by clicking on the “Security” tab on your browser. Note that Organogenesis is located in the United States, and the U.S. has not yet been determined to have “adequate” data privacy safeguards by the EU; despite any inherent risks in the transfer of data from the EU, Organogenesis takes the security of your information seriously. To read our privacy policy, click here.

Literature Library

1. Armstrong DG. The Efficacy of Apligraf in the Treatment of Diabetic Foot Ulcers. Plast. Reconstr. Surg. 2006; 117(Suppl.): 158S-159S.
2. Atillasoy E. The Safety and Efficacy of Graftskin (Apligraf) in the Treatment of Venous Leg Ulcers: A Multicenter, Randomized, Controlled Clinical Trial. Wounds. 2000; 12(5 Suppl A):20A-26A.
3. Becker HD, Beckert S and Coerper S. Skin Grafting of Venous Ulcers: A Review of its Current Role Int J Low Extrem Wounds. 2002; 1: 236.
4. Bello YM, Falabella AF. The role of graftskin (Apligraf) in difficult-to-heal venous leg ulcers. J Wound Care. 2002; 11(5):182-3.
5. Boulton Andrew JM, Kirsner Robert S, Vileikyte Loretta. Neuropathic Diabetic Foot Ulcers. New Engl J Med. 2004; 351:48-55.
6. Brem H. Protocol for the Successful Treatment of Venous Ulcers. Amer. J. of Surg. 2004; 188(Suppl. 1A):1S-8S.
7. Brem Harold, Sheehan Peter, Boulton Andrew JM. Protocol for Treatment of Diabetic Foot Ulcers. American Journal of Surgery. 2004; 187(May Supplement): 1S-10S.
8. Brem H, Young J, Isaacs C, Tomic-Canic M, Ehrlich Paul. Clinical Efficacy and Mechanisms of Bilayered Living Human Skin Equivalent (HSE) in Treatment of Diabetic Foot Ulcers. Surgical Technology International XI. May 2003; 23-31.
9. Brem H, Balledux J, Sukkarieh T, Cason, P and Falanga V. Healing of venous ulcers of long duration with a bilayered living skin substitute: results from a general surgery and dermatology department. Dermatol Surg. 2001; 27:915-919.
10. Cavorsi JP. Evidence-Based Wound Care Standards in the Clinical Setting: Applying the Knowledge to Real-World Practice. Supplement to Wounds September 2007: 9-12.
11. Cavorsi J, et al. Best Practices Algorithms for the use of a Bilayered Living Cell Therapy Apligraf in the Treatment of Lower Extremity Ulcers. Wound Rep Reg. 2006; 14:102–109.
12. Chow I, Lemos EV, Einarson TR. Management and prevention of diabetic foot ulcers and infections: a health economic review. Pharmacoeconomics. 2008; 26(12):1019-35.
13. DeCarbo WT. Bilayered Bioengineered Skin Substitute to Augment Wound Healing. Foot & Ankle Specialist Dec 2009 2(6): 303-305.
14. DeCarbo WT. Apligraf: Bilayered Skin Substitute to Augment Wound Healing of Chronic Wounds in Diabetic Patients. Foot & Ankle Specialist Dec 2009 2(6): 299-302.
15. Edmonds M. Apligraf in the Treatment of Neuropathic Diabetic Foot Ulcers. International Journal of Lower Extremity Wounds. 2009; 8(1):11-18.
16. Fahey C. Experience with a new human skin equivalent for healing venous leg ulcers. J Vasc Nurs. 1998; 16(1):11-5.
17. Falanga, V., et al: Wound Bed Score and its Correlation with Healing of Chronic Wounds. Dermatologic Therapy. 2006; 19:383-390.
18. Falanga V. Bioengineered skin. Wounds. 2000; 12(6 Suppl B):99B-105B.
19. Falanga V, Sabolinski ML. Prognostic factors for healing of venous and diabetic ulcers. Wounds. 2000; 12(5 Suppl A):42A-46A.
20. Falanga V and Sabolinski M. A Bilayered Living Skin Construct (Apligraf®) Accelerates Complete Closure of Hard-to-Heal Venous Ulcers. Wound Repair and Regeneration. 1999; 7(4):201-207.
21. Falanga V. How to Use Apligraf to Treat Venous Ulcers. Skin & Aging, February 1999:30-36.
22. Falanga, V., et al: Rapid Healing of Venous Ulcers and Lack of Clinical Rejection with an Allogeneic Cultured Human Skin Equivalent. Arch. Dermatol. 1998; 134: 293-300.
23. Farah RS, Davis MD. Venous leg ulcerations: a treatment update. Curr Treat Options Cardiovasc Med. 2010 Apr;12(2):101-16.
24. Fivenson D, Scherschun L. Clinical and economic impact of Apligraf for the treatment of nonhealing venous leg ulcers. Int J Dermatol. 2003 Dec; 42(12):960-5.
25. Hanft JR and Henao M. Current concepts with bioengineered alternative tissues. Podiatry Today. 2010 July: 60-65.
26. Harding K, Cutting K, Price P. The cost-effectiveness of wound management protocols of care. Br J Nurs. 2000; 9(19 Suppl): S6, S8, S10 passim.
27. Hunt NA, Liu GT, Lavery LA. The economics of limb salvage in diabetes. Plast Reconstr Surg. 2011 Jan;127 Suppl 1:289S-295S.
28. Jones JE, Nelson EA. Skin grafting for venous leg ulcers. Cochrane Database of Systematic Reviews 2007, Issue 2, Art. No.:CD001737
29. Karr JC. Retrospective Comparison of Diabetic Foot Ulcer and Venous Stasis Ulcer Healing Outcome Between a Dermal Repair Scaffold (PriMatrix) and a Bilayered Living Cell Therapy (Apligraf). Adv Skin Wound Care. 2011 Mar: 119-125.
30. Kerstein Morris D., et al: Development of a Severity Scale for Evaluating the Need for Graftskin in Nonhealing Ulcers. Adv in Skin Wound Care. 2002; 15(2):66-71.
31. Kim P, Heilala M, Steinberg J, Weinraub G. Bioengineered alternative tissues and hyperbaric oxygen in lower extremity wound healing. Clin Podiatr Med Surg. 2007 Jul;24(3):529-46.
32. Kirsner RS, Warriner R, Michela M, Stasik L and Freeman K. Advanced biological therapies for diabetic foot ulcers. Arch Dermatol. 2010 Aug;146(8):857-862.
33. Kirsner RS. The Science of Bilayered Cell Therapy. Supplement to Wounds Sept 2005.
34. Kirsner RS, Fastenau J, Falabella A, Valencia I, Long R, Eaglstein WH. Clinical and economic outcomes with Graftskin for hard-to-heal venous leg ulcers: a single-center experience. Dermatol Surg. 2002; 28:81-82
35. Kirsner R, Falanga V, Fivenson D, Thibodeaux K, Cavorsi J, de la Pava D, Brem H, Golomb CA. Clinical Experience with a Human Skin Equivalent for the Treatment of Venous Leg Ulcers: Process and Outcomes. Wounds. 1999; 11(6):137-144.
36. Kuhn C, Angehrn F. Use of high-resolution ultrasound to monitor the healing of leg ulcers: a prospective single-center study. Skin Research and Technology. 2009: 1–7.
37. Landsman AS, et al. A Retrospective Clinical Study of 188 Consecutive Patients to Examine the Effectiveness of a Biologically Active Cryopreserved Human Skin Allograft (Theraskin) on the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Foot Ankle Spec 2011 4: 29 originally published online 6 December 2010
38. Langer A, Rogowski W. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Services Research. 2009, 9:115.
39. MacKay G. Bioactive wound healing, bioaesthetics and biosurgery: three pillars of product development. Interview with Geoff MacKay. Regen Med. 2006 Mar; 1(2):169-74.
40. Mason, C and Manzotti, E. Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010. Regen. Med. 2010; 5(3): 307–313.
41. Masseth R. Apligraf: A Promising New Wound Care Treatment for the 21st Century. J of National Assoc. Ortho Tech. Spring 2002:22-25.
42. Mathias SD, Prebil LA, Boyko WL, Fastenau J. Health-related quality of life in venous leg ulcer patients successfully treated with Apligraf: a pilot study. Adv Skin Wound Care. 2000; 13(2):76-8.
43. Moneta G. Graftskin (Apligraf) in the treatment of venous leg ulcer: optimal application techniques. Wounds. 2000; 12(5 Suppl A):27A-32A.
44. Moneta G. et al, Skin Substitute Consensus Development Panel. Nonoperative Management of Venous Leg Ulcers: Evolving Role of Skin Substitutes. Vascular Surgery.1999; 33(2).
45. Nelson EA, Jones J. Venous leg ulcers. Clinical Evidence 2008;09:1902
46. Noel B. Economic assessment of Apligraf for the treatment of venous leg ulcers. Wound Repair Regen. 2001; 9(1): 60.
47. O’Donnell TF, Lau J. A systematic review of randomized controlled trials of wound dressings for chronic venous ulcer. J Vasc Surg. 2006; 44:1118-25.
48. Pham, H.T., et al: Evaluation of a Human Skin Equivalent for the Treatment of Diabetic Foot Ulcers in a Prospective, Randomized, Clinical Trial. Wounds. 1999; 11(4): 79-86.
49. Phillips TJ, Manzoor J, Rojas A, Isaacs C, Carson P, Sabolinski M, Young J, Falanga V. The longevity of a bilayered skin substitute after application to venous ulcers. Arch Dermatol. 2002; 138(8):1079-81.
50. Phillips TJ. New Skin for Old. Arch of Dermatol. 1998; (134):344-349.
51. Plotner AN and Mostow EN. A review of bioactive materials and chronic wounds. Cutis. 2010; 85:259-266.
52. Pollak R. Use of Graftskin (Apligraf) in diabetic foot ulcers: case presentations. Wounds. 2000; 12(5 Suppl A):37A-41A.
53. Redekop WK, McDonnell J, Verboom P, Lovas K, Kalo Z. The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics. 2003; 21(16):1171-83.
54. Saap Liliana J., Falanga Vincent. Debridement Performance index and its correlation with complete closure of diabetic foot ulcers. Wound Rep Reg. 2002; 10: 354-359.
55. Sabolinski ML and Bilbo PR. The Clinical Experience of Bioengineered Skin Products. In Falanga, V., eds. Cutaneous Wound Healing. Martin Dunitz; 2001: 411-431.
56. Sabolinski ML, Veves A. Graftskin (Apligraf) in neuropathic diabetic foot ulcers. Wounds. 2000; 12(5 Suppl A):33A-36A.
57. Sabolinski, M.L., et al: Cultured Skin as a Smart Material for Healing Wounds: Experience in Venous Ulcers. Biomaterials 17: 311-320, 1996
58. Samies, JH. Infection and Pain Control in Wound Care: Getting the Most out of Bilayered Living Cell Therapy. Evidence-Based Wound Care Standards in the Clinical Setting: Applying the Knowledge to Real-World Practice. Supplement to Wounds. September 2007: 9-12.
59. Sams HH, Chen J, King LE. Graftskin treatment of difficult to heal diabetic foot ulcers: one center's experience. Dermatol Surg. 2002; 28(8):698-703.
60. Schonfeld, W.H., et al: An economic assessment of Apligraf for the treatment of hard-to-heal venous leg ulcers. Wound Repair and Regeneration. 2000: 8(4): 251-257.
61. Shafritz R. Combining Bilayered Living Cell Therapy with Minimally Invasive Vein Surgery: Current Treatment Strategies for Venous Ulcers. Supplement to Vascular Disease Management. March/April 2007: 4-10.
62. Sibbald RG, Torrance GW, Walker V, Attard C, MacNeil P. Cost-effectiveness of Apligraf in the treatment of venous leg ulcers. Ostomy Wound Manage. 2001; 47(8): 36-46.
63. Sibbald RG. Apligraf Living Skin Equivalent for Healing Venous and Chronic Wounds. Journal of Cutaneous Medicine and Surgery. 1998; 3(Suppl 1): S1-24-S1-28.
64. Snyder R. Tips on Using Apligraf. Podiatry Management. 2008: August:169-170.
65. Snyder R. The Quality of Care and Economic Benefits of Utilizing Apligraf in Clinical Practice. Podiatry Management. 2008: January:201-208.
66. Steinberg JS, Edmonds M, Hurley DP, King WN. Confirmatory Data from EU Study Supports Apligraf for the Treatment of Neuropathic Diabetic Foot Ulcers. J Am Podiatr Med Assoc. 2010; 100(1):73.
67. Steinberg J. Putting Bilayered Cell Therapy to Use. Supplement to Wounds. 2005; September.
68. Steinberg J, et al: A Cost Analysis of a Living Skin Equivalent in the Treatment of Diabetic Foot Ulcers. Wounds. 2002; 14(4):142-149.
69. Steinberg J and Ho T. Apligraf: how effective is it? Podiatry Today. 2001; September.
70. Steinberg J. How you can use Apligraf to treat diabetic foot ulcers. Podiatry Today. 2000; September.
71. Streit M, Braathen LR. Apligraf – a living human skin equivalent for the treatment of chronic wounds. Int J Artif Organs. 2000 Dec; 25(12):831-3.
72. Teng YJ, et al: Bioengineered skin in diabetic foot ulcers. Diabetes Obes Metab. 2010 Apr; 12(4):307-15.
73. Veves A., et al: Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001; 24(2):290-295.
74. White R, McIntosh C. A review of the literature on topical therapies for diabetic foot ulcers. Part 2: Advanced treatments. J Wound Care. 2009 Aug; 18(8):335-41. Review.
75. Woo K, Ayello EA, Sibbald RG. The Edge Effect: Current Therapeutic Options to Advance the Wound Edge. Advances in Skin & Wound Care. 2007; 20:99-117, quiz 118-9.